A clinical randomized controlled study of electroacupuncture combined with microneedle knife in the treatment of moderate to severe allergic rhinitis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500099796

Enrollment

Unknown

Registered

2025-03-28

Start date

2025-04-11

Completion date

Unknown

Last updated

2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

Electroacupuncture combined with microneedle knife:The patient takes the supine position, the acupoints take bilateral Yingxiang acupoints and upper Yingxiang acupoints, the tip of the needle is stabb

and then the patient takes the seated position, with his head hanging down low on the therapeutic pillow, and the therapeutic point of occipitocervical segment is selected, Then the patient is placed

drug group:Give cetirizine hydrochloride tablets, 1 tablet daily. Also nasal budesonide spray, administration: starting dose is 2 sprays in each nostril twice daily, after 3 days reduce to 1 spray in

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Those with clinical and laboratory diagnosis of moderate to severe allergic rhinitis; 2. Aged >=18 years and <=75 years, with no restriction on gender or ethnicity; 3. Not taking drugs such as antihistamines or nasal steroids within 1 month before enrollment; 4. Those who voluntarily participated in this study and signed an informed consent form, and who were able to adhere to outpatient treatment for 4 weeks.

Exclusion criteria

Exclusion criteria: 1. Atrophic rhinitis, hypertrophic rhinitis, vasomotor rhinitis, acute and chronic sinusitis, nasal polyps, severe septal deviation, eosinophilia non-allergic rhinitis; 2. Those with other allergic diseases such as asthma, urticaria, and colds that cause nasal congestion, runny nose, and sneezing; 3.Those who have serious diseases such as cardiovascular, cerebrovascular, hepatic, renal and hematopoietic systems in combination; 4.Pregnant or lactating women, psychiatric patients, patients with malignant tumors.

Design outcomes

Primary

Measure	Time frame
Total Nasal Symptom Score,TNSS;	—

Secondary

Measure	Time frame
Total Non-nasal Symptom Score,TNNSS;Rhinitis Quality of Life Questionnaire,RQLQ;Serum chemokines;Inter Cellular Adhesion Molecule-1,ICAM-1;Eosinophil Cationic Protein,ECP;	—

Countries

China

Contacts

Public ContactPengfei Qiu

Zhejiang Hospital

764360784@qq.com+86 181 5850 8449

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026